Lee; William Y. - US Patent Attorneys and Agents

Attorney: Lee; William Y.

Number of patents: 52
Last date: January 11, 2011

Browse patents
Browse applications

Number	Title	Issue Date
7868000	Aspartyl protease inhibitors Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein j, k, U, W, R, R1, R2, R3, R4, R6,...	01/11/2011
7812013	Macrocyclic heterocyclic aspartyl protease inhibitors Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt, solvate or ester thereof, wherein U, W, X, L, Y, M, Z, c, d, e, f, g, h, s, t, R1, R2, R7...	10/12/2010
7763609	Heterocyclic aspartyl protease inhibitors Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(═S)—, —S(O)—, —S(O)2	07/27/2010
7763606	Heterocyclic aspartyl protease inhibitors Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein Ar, R1, R2, R3, R4 and R5 are as d...	07/27/2010
7759354	Bicyclic guanidine derivatives as asparyl protease inhibitors, compositions, and uses thereof The present application provides compounds of the Formula: and stereoisomers, tautomers, or pharmaceutically acceptable salts and solvates thereof, wherein U, W, R, R1, R2, R3 and R4	07/20/2010
7759353	Substituted spiro iminopyrimidinones as aspartyl protease inhibitors, compositions, and methods of treatment Disclosed are certain substituted spiro iminopyrimidinones and other compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein U, W, A, R, R1, R2...	07/20/2010
7718702	Cannabinoid receptor ligands There are disclosed compounds of the formula a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; which exhibit anti-inflammatory and immunodulatory activity....	05/18/2010
7713985	Adenosine Areceptor antagonists Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein: X1 and X2 are 1-3 substituents independently selected from the group...	05/11/2010
7709492	Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A receptor antagonists Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl or...	05/04/2010
7700603	Heterocyclic aspartyl protease inhibitors Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(═S)—, —S(O)—, —S(O)2	04/20/2010
7700597	Substituted piperazines as CB1 antagonists Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinf...	04/20/2010
7652003	Macrocyclic β-secretase inhibitors Disclosed are novel compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, n and X are as defined in the sp...	01/26/2010
7642272	Cannabinoid receptor ligands There are disclosed compounds of the formula I a pharmaceutically acceptable salt or solvate of the compound, which exhibit anti-inflammatory and immunomodulatory activity. Also disclosed are pharmaceutical compositions con...	01/05/2010
7592348	Heterocyclic aspartyl protease inhibitors Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(═S)—, —S(O)—, —S(O)2	09/22/2009
7560451	Aspartyl protease inhibitors Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W, R1, R2, R3, R4, R5, R6	07/14/2009
7511146	2-substituted benzimidazole piperidines analogs as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders The present invention discloses compounds of formula I wherein Ar, Y, m, n, R1 and R4 are herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as meth...	03/31/2009
7498441	Biaryltetrahydroisoquinoline piperidines as selective MCH receptor antagonists for the treatment of obesity and related disorders The present invention discloses compounds which are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In other aspects, the invention is directed to pharmaceutical compositions comprising such MCH antagonists...	03/03/2009
7488752	Thrombin receptor antagonists Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein z,1 represents an optional double bond, the dotted line is optionally a...	02/10/2009
7482360	Fused tetracyclic mGluR1 antagonists as therapeutic agents In its many embodiments, the present invention provides tetracyclic compounds of formula I or formula II (wherein the various moieties are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutam...	01/27/2009
7459450	Neuropeptide receptor modulators The present invention discloses compounds, which are novel receptor antagonists for NPY Y1 as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such NPY Y1 receptor antagonists as well...	12/02/2008
7452891	MCH antagonists and their use in the treatment of obesity The present invention discloses compounds which, are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonist...	11/18/2008
7423149	Substituted n-aryl amidines as selective D dopamine receptor antagonists for the treatment of obesity and CNS disorders The present invention provides compounds, which, are novel antagonists for D1 receptors as well as methods for preparing such compounds. In another embodiment, the invention provides pharmaceutical compositions comprising such D1 receptor antag...	09/09/2008
7414058	Adenosine Areceptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders There is disclosed a method for the treatment of Extra Pyramidal syndrome (EPS) comprising the administration of an adenosine A2a receptor antagonist, alone or in combination with other agents useful for treating EPS. ...	08/19/2008
7361769	Heterocyclyls as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders The present invention discloses compounds of formula I wherein m, n, p, R1, R2 and X, are herein defined, the compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as metho...	04/22/2008
7348328	MCH antagonists for the treatment of obesity The present invention discloses compounds which, are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonist...	03/25/2008
7345042	MCH antagonists for the treatment of obesity The present invention discloses methods of using antagonists for melanin-concentrating hormone (MCH), to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes, as well as novel compounds which are antagonists for melanin-concentratin...	03/18/2008
7304076	Neuropeptide Y Y5 receptor antagonists The present invention discloses compounds which, are novel receptor antagonists for NPY Y5 as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such NPY Y5 receptor antagonists as well...	12/04/2007
7253189	Cannabinoid receptor ligands A compound of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein: R1, R2, L1, L2, M1, M2, n, p, q, A, D, X, Y and Z are...	08/07/2007
7217732	Cannabinoid receptor agonists A compound of the formula or a pharmaceutically acceptable salt thereof, wherein: R1, R2, R3, R4, R5, R6, L1, L2	05/15/2007
7214691	2-substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders The present invention discloses compounds of formula I wherein Ar, X, R1 and R11 are herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well a...	05/08/2007
7211574	Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders The present invention provides compounds, which, are novel antagonists for D1/D5 receptors as well as methods for preparing such compounds. In another embodiment, the invention provides pharmaceutical compositions comprising such D1/...	05/01/2007
7157472	Neuropeptide Y Y5 receptor antagonists The present invention discloses compounds which, are receptor antagonists for NPY Y5 as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such NPY Y5 receptor antagonists as well as me...	01/02/2007
7109207	Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity The present invention discloses compounds which, are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonist...	09/19/2006
7087751	Synthesis of temozolomide and analogs This invention relates to a novel process for the synthesis of Temozolomide, an antitumor compound, and analogs, and to intermediates useful in this novel process. ...	08/08/2006
7078408	[1,2,4]-Triazole bicyclic adenosine A2a receptor antagonists Compounds having the structural formula I wherein: n is 0, 1, 2 or 3; A is C(R1) or N; R1 and R1a are H, (C1–C6)-alkyl, halo,...	07/18/2006
7045636	MCH antagonists for the treatment of obesity The present invention discloses compounds, which are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonist...	05/16/2006
7037920	Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salts thereof, wherein: n1 and n2 are independently 0-2; Het...	05/02/2006
7030113	Aminobenzimidazoles as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders The present invention discloses compounds of formula I wherein Ar, Z, m, n, p, R1 and R8 are herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well ...	04/18/2006
6982267	Heteroaryl urea neuropeptide Y Y5 receptor antagonists The present invention relates to compounds represented by the structural Formula I: or a pharmaceutically acceptable salt thereof, which are useful for the treatment of metabolic and eating disorders such as obesity an...	01/03/2006
6946476	Heteroaryl urea neuropeptide Y Y5 receptor antagonists The present invention relates to compounds represented by the structural Formula I: or a pharmaceutically acceptable salt thereof, which are useful for the treatment of metabolic and eating disorders such as obesity an...	09/20/2005

«First «Previous1 2 Next»Last»

PatentStorm

Quotables

PatentStorm News

Attorney: Lee; William Y.